Mankind Pharma Q1 Results: Profit Rises 66%, Beats Estimates
Mankind Pharma Ltd. reported a 66% surge in profit in the first quarter of FY24, beating analysts' estimates.
The Delhi-headquartered drugmaker's consolidated net profit rose to Rs 487 crore in the April-June quarter, according to its exchange filing. That compares with the Rs 398 crore consensus estimate of analysts tracked by Bloomberg.
Sequentially, the profit jumped 71%.
Mankind Pharma Q1 FY24 Highlights (YoY)
Revenue rose 18% to Rs 2,579 crore, as against an estimate of Rs 2,446 crore.
Ebitda was up 44% at Rs 655 crore, as compared with a forecast of Rs 560 crore.
Margin stood at 25.4% versus 20.9%. Analysts had estimated it at 22.9%.
Other Highlights (YoY)
Domestic sales grew 14% with a revenue of Rs 2,419 crore, of which consumer healthcare rose 8%.
The company ranked fourth in the domestic market, with a market share of 4.4% in Q1 FY24, as against 4.2% in Q1 FY23.
Its chronic growth was 17%, as compared with Indian pharma market growth of 10% in Q1 FY24.
Exports surged 214% to Rs 160 crore, aided by certain one-off opportunities in the U.S., the company said in the filing.
For the export market, the filing said that the new integrated API/formulation manufacturing plant is expected to be commercialised in H1 FY24.
The company is exploring export of Dydrogesterone (treatment of menstrual disorders) to key markets.
"We have started the year on a healthy note, with strong double-digit growth in sales and profitability," said Rajeev Juneja, vice chairman and managing director at the company, in the filing.
The company's pharma segment outperformed the Indian pharma market by 1.5 times, led by volume-led growth and the highest-ever chronic share, he said. The consumer healthcare segment maintained dominant brand leadership in respective categories, according to him.
"Our market-disruptive 'DMF Quality Products' campaign has seen an outstanding response, and we are rapidly expanding our product offerings in this important initiative," Juneja said.
Shares of Mankind Pharma closed 1.81% lower on Wednesday as compared with a 1.02% decline in the benchmark Sensex.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
